This user has not added any information to their profile yet.
Company Profile
Egis Pharmaceuticals PLC is one of the leading generic pharmaceutical companies in the CEE and CIS regions with activities extending to every field of pharmaceutical production from research and development, through active ingredient and finished production to sales and marketing.
In our home country, Hungary, our APIs and drugs are developed and produced at three production sites. Over more than one hundred years that have passed since the foundation of our company in 1913, Egis has grown into an internationally renowned company with 4364 employees worldwide. Our successes have been established by our company’s founding CEO, the pharmacist Sándor Balla, who laid great emphasis not only on manufacturing high-quality products but on the export and R&D as well, which ensured our continuous growth.
To this day, these are the key pillars of Egis’ development. We devote a regionally outstanding amount to research and development. In the past years we have renewed and significantly increased our innovation capacities. At each of our three production sites we have constructed R&D centers, where high value added – e.g. combination – products are developed providing modern, cost-effective therapies for the patients.
Our products are sold to 62 countries and 77% our turnover derived from export. Besides Hungary, we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices. Our drugs acting on the cardiovascular, central nervous and respiratory systems account for two-thirds of our turnover and we continuously open towards new areas. In 2013 Egis launched Europe’s first biosimilar monoclonal antibody and it is our strategic goal to become a key player in the biosimilar therapies’ segment.
Egis’s products are available in Vietnam from the mid of 1950’s. Currently the company selling 45 type of SKU of 29 active ingredients in Vietnam. Our main focus in Vietnam in line with our global strategy Neurology and Cardiology therapies but we have reasonable OTC portfolio as well treating Respiratory diseases.
Company Information
Company Description
Egis Pharmaceuticals PLC is one of the leading generic pharmaceutical companies in the CEE and CIS regions with activities extending to every field of pharmaceutical production from research and development, through active ingredient and finished production to sales and marketing.
In our home country, Hungary, our APIs and drugs are developed and produced at three production sites. Over more than one hundred years that have passed since the foundation of our company in 1913, Egis has grown into an internationally renowned company with 4364 employees worldwide. Our successes have been established by our company’s founding CEO, the pharmacist Sándor Balla, who laid great emphasis not only on manufacturing high-quality products but on the export and R&D as well, which ensured our continuous growth.
To this day, these are the key pillars of Egis’ development. We devote a regionally outstanding amount to research and development. In the past years we have renewed and significantly increased our innovation capacities. At each of our three production sites we have constructed R&D centers, where high value added – e.g. combination – products are developed providing modern, cost-effective therapies for the patients.
Our products are sold to 62 countries and 77% our turnover derived from export. Besides Hungary, we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices. Our drugs acting on the cardiovascular, central nervous and respiratory systems account for two-thirds of our turnover and we continuously open towards new areas. In 2013 Egis launched Europe’s first biosimilar monoclonal antibody and it is our strategic goal to become a key player in the biosimilar therapies’ segment.
Egis’s products are available in Vietnam from the mid of 1950’s. Currently the company selling 45 type of SKU of 29 active ingredients in Vietnam. Our main focus in Vietnam in line with our global strategy Neurology and Cardiology therapies but we have reasonable OTC portfolio as well treating Respiratory diseases.
Business Category
Number of Employees in Vietnam
Company Name
Address
Telephone
2nd Address
2nd Telephone
2nd Email
Fax
Website
Log in as a member to access the details. Not a member? Contact our Membership team at (84-28) 3827 2715 ext 105 or membership@eurochamvn.org
This user has not added any information to their profile yet.
Company Profile
Egis Pharmaceuticals PLC is one of the leading generic pharmaceutical companies in the CEE and CIS regions with activities extending to every field of pharmaceutical production from research and development, through active ingredient and finished production to sales and marketing.
In our home country, Hungary, our APIs and drugs are developed and produced at three production sites. Over more than one hundred years that have passed since the foundation of our company in 1913, Egis has grown into an internationally renowned company with 4364 employees worldwide. Our successes have been established by our company’s founding CEO, the pharmacist Sándor Balla, who laid great emphasis not only on manufacturing high-quality products but on the export and R&D as well, which ensured our continuous growth.
To this day, these are the key pillars of Egis’ development. We devote a regionally outstanding amount to research and development. In the past years we have renewed and significantly increased our innovation capacities. At each of our three production sites we have constructed R&D centers, where high value added – e.g. combination – products are developed providing modern, cost-effective therapies for the patients.
Our products are sold to 62 countries and 77% our turnover derived from export. Besides Hungary, we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices. Our drugs acting on the cardiovascular, central nervous and respiratory systems account for two-thirds of our turnover and we continuously open towards new areas. In 2013 Egis launched Europe’s first biosimilar monoclonal antibody and it is our strategic goal to become a key player in the biosimilar therapies’ segment.
Egis’s products are available in Vietnam from the mid of 1950’s. Currently the company selling 45 type of SKU of 29 active ingredients in Vietnam. Our main focus in Vietnam in line with our global strategy Neurology and Cardiology therapies but we have reasonable OTC portfolio as well treating Respiratory diseases.
Company Information
